Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Abbott Laboratories



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.0%. By the end of trading, Abbott Laboratories rose $0.80 (2.1%) to $38.56 on average volume. Throughout the day, 8,420,790 shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7,319,200 shares. The stock ranged in a price between $37.95-$38.64 after having opened the day at $37.98 as compared to the previous trading day's close of $37.76. Other companies within the Health Care sector that increased today were:




), up 26.9%,

Sinovac Biotech



), up 20.5%,

BG Medicine



), up 13.4% and

Biosante Pharmaceuticals



), up 12.1%.

  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $58.9 billion and is part of the health services industry. The company has a P/E ratio of 9.8, below the S&P 500 P/E ratio of 17.7. Shares are up 15.3% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share.

On the negative front,




), down 34.7%,

Oxygen Biotherapeutics



), down 12.9%,

China Pharma



), down 10.6% and

Tianyin Pharmaceutical



), down 9.7% , were all laggards within the health care sector with

Warner Chilcott



) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.